Pfizer’s effort to join the weight-loss drug craze just hit a major setback. Patients are quitting its trial after experiencing unpleasant side effects. We’ll bring you the details, and the stock reaction.
Plus, our Retail Ecosystem series concludes with a look at luxury stocks. Is the high-end consumer still buying, or spending money elsewhere on things like experiences? We’ll ask an industry insider.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
